[go: up one dir, main page]

MXPA03003339A - Metodos para modular la funcion de la vejiga. - Google Patents

Metodos para modular la funcion de la vejiga.

Info

Publication number
MXPA03003339A
MXPA03003339A MXPA03003339A MXPA03003339A MXPA03003339A MX PA03003339 A MXPA03003339 A MX PA03003339A MX PA03003339 A MXPA03003339 A MX PA03003339A MX PA03003339 A MXPA03003339 A MX PA03003339A MX PA03003339 A MXPA03003339 A MX PA03003339A
Authority
MX
Mexico
Prior art keywords
methods
bladder function
modulating bladder
modulating
function
Prior art date
Application number
MXPA03003339A
Other languages
English (en)
Inventor
Thomas Michael Argentieri
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03003339(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA03003339A publication Critical patent/MXPA03003339A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/341—Urinary incontinence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03003339A 2000-10-17 2001-10-16 Metodos para modular la funcion de la vejiga. MXPA03003339A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24107800P 2000-10-17 2000-10-17
US28142801P 2001-04-04 2001-04-04
PCT/US2001/032204 WO2002032419A2 (en) 2000-10-17 2001-10-16 Methods for modulating bladder function

Publications (1)

Publication Number Publication Date
MXPA03003339A true MXPA03003339A (es) 2003-06-19

Family

ID=26933980

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003339A MXPA03003339A (es) 2000-10-17 2001-10-16 Metodos para modular la funcion de la vejiga.

Country Status (22)

Country Link
US (3) US6348486B1 (es)
EP (2) EP1326597B1 (es)
JP (2) JP2004511516A (es)
KR (1) KR20030040540A (es)
CN (1) CN1287781C (es)
AR (1) AR030901A1 (es)
AT (1) ATE314061T1 (es)
AU (2) AU2002211758A1 (es)
BR (1) BR0114718A (es)
CA (2) CA2450467C (es)
CY (1) CY1105353T1 (es)
DE (1) DE60116352T2 (es)
DK (1) DK1326597T3 (es)
ES (1) ES2253432T3 (es)
HU (1) HUP0303288A2 (es)
IL (1) IL155090A0 (es)
MX (1) MXPA03003339A (es)
NO (1) NO20031580L (es)
NZ (1) NZ525301A (es)
PL (1) PL360903A1 (es)
TW (1) TWI287984B (es)
WO (2) WO2002032419A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP2006513154A (ja) * 2002-10-21 2006-04-20 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド カリウムチャネルおよび／または皮質ニューロン活性モジュレーターとしての、ｎ−フェニルアントラニル酸および２−ベンズイミダゾロンの誘導体
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20060264496A1 (en) * 2003-04-25 2006-11-23 H. Lundbeck A/S Substituted indoline and indole derivatives
US20070292528A1 (en) * 2003-05-06 2007-12-20 University Hospital Of Basel Kcnma1 as a Therapeutic Target in Cancer Treatment
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2007084497A1 (en) * 2006-01-19 2007-07-26 Wyeth A novel rat voltage-gated potassium channel
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8293911B2 (en) * 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) * 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
DE102007012029A1 (de) 2007-03-13 2008-09-18 Grünenthal GmbH Verfahren zur Identifizierung der agonistischen Aktivität einer Zielverbindung auf einen Kaliumkanal
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
KR101522747B1 (ko) 2007-08-06 2015-05-26 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2203411B1 (en) * 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
HUE041370T2 (hu) * 2008-05-21 2019-05-28 Ferring Bv Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
CN102170879B (zh) * 2008-07-18 2014-03-05 威朗国际制药公司 调控释放制剂及其应用方法
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2011101456A2 (en) * 2010-02-19 2011-08-25 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
CA2870095A1 (en) 2012-04-30 2013-11-07 Scifluor Life Sciences, Llc Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
WO2019203951A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
US20230049231A1 (en) * 2019-10-07 2023-02-16 D. E. Shaw Research, Llc ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
MX2022004144A (es) * 2019-10-07 2022-06-14 De Shaw Res Llc Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
MX2023009314A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37460A (en) * 1863-01-20 Improvement in meat-broilers
GB9220570D0 (en) * 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US6403360B1 (en) * 1997-08-12 2002-06-11 Bristol-Myers Squibb Company KCNQ potassium channels and methods of modulating same
CA2307316C (en) * 1997-10-24 2010-12-21 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
WO1999041372A1 (en) * 1998-02-17 1999-08-19 Astrazeneca Uk Limited Potassium channel polypeptide
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
DE60031241T2 (de) * 1999-01-26 2007-02-08 Neurosearch A/S Kaliumkanäle und für diese kaliumkanäle kodierende gene
US6794161B1 (en) * 1999-01-26 2004-09-21 Neurosearch A/S Potassium channels and genes encoding these potassium channels
IT1312224B1 (it) * 1999-03-23 2002-04-09 Cit Alcatel Circuito pre/post-distorcitore particolarmente per sistemi aradiofrequenza microonde.
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6617131B2 (en) * 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
EP1272634A1 (en) * 2000-04-03 2003-01-08 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6613786B2 (en) * 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
JP2007520996A (ja) * 2003-01-15 2007-08-02 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ４４３９０、５４１８１、２１１、５６８７、８８４、１４０５、６３６、４４２１、５４１０、３０９０５、２０４５、１６４０５、１８５６０、２０４７、３３７５１、５２８７２、１４０６３、２０７３９、３２５４４、４３２３９、４４３７３、５１１６４、５３０１０、１６８５２、１５８７、２２０７、２２２４５、２３８７、５２９０８、６９１１２、１４９９０、１８５４７、１１５、５７９、１５９８５、１５６２５、７６０、１８６０３、２３９５、２５５４、８６７５、３２７２０、４８０９、１４３０３、１６８１６、１７８２７、３２６２０、５７７、６１９、１４２３、２１５８、８２６３、１５４０２、１６２０９、１６３８６、２１１６５、３０９１１、４１８９７、１６４３、２５４３、９６２６、１３２３１、３２４０９、８４２６０、２８８２、８２０３、３２６７８または５５０５３を用いて泌尿器科障害を処置するための方法および組成物
EP1640021A4 (en) * 2003-06-30 2008-01-23 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF HARVESE DISORDERS
CA2536633A1 (en) * 2003-09-10 2005-03-24 Icagen, Inc. Fused ring heterocycles as potassium channel modulators
BRPI0609952A2 (pt) * 2005-04-24 2010-05-11 Wyeth Corp métodos para modular a função da bexiga
WO2007084497A1 (en) * 2006-01-19 2007-07-26 Wyeth A novel rat voltage-gated potassium channel

Also Published As

Publication number Publication date
CY1105353T1 (el) 2010-03-03
DK1326597T3 (da) 2006-02-13
DE60116352D1 (de) 2006-02-02
EP1326597A2 (en) 2003-07-16
ES2253432T3 (es) 2006-06-01
BR0114718A (pt) 2003-10-14
NO20031580L (no) 2003-06-14
CN1469739A (zh) 2004-01-21
KR20030040540A (ko) 2003-05-22
DE60116352T2 (de) 2006-06-22
CA2450467A1 (en) 2002-04-25
AU2002213308A1 (en) 2002-04-29
NZ525301A (en) 2004-10-29
EP1326597B1 (en) 2005-12-28
WO2002032960A2 (en) 2002-04-25
NO20031580D0 (no) 2003-04-08
WO2002032419A3 (en) 2002-08-15
CA2450467C (en) 2011-05-24
PL360903A1 (en) 2004-09-20
US20060252104A1 (en) 2006-11-09
CA2425742A1 (en) 2002-04-25
US20050101004A1 (en) 2005-05-12
HUP0303288A2 (hu) 2004-01-28
US6348486B1 (en) 2002-02-19
WO2002032960A3 (en) 2003-04-17
ATE314061T1 (de) 2006-01-15
CN1287781C (zh) 2006-12-06
JP2004511516A (ja) 2004-04-15
HK1056514A1 (en) 2004-02-20
US7160684B2 (en) 2007-01-09
JP2004529611A (ja) 2004-09-30
TWI287984B (en) 2007-10-11
AU2002211758A1 (en) 2002-04-29
AR030901A1 (es) 2003-09-03
WO2002032419A2 (en) 2002-04-25
IL155090A0 (en) 2003-10-31
EP1328550A2 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
MXPA03003339A (es) Metodos para modular la funcion de la vejiga.
MXPA03002410A (es) 4-amino-quinazolinas.
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
ZA200205479B (en) Novel biarylcarboxamides.
MXPA03002256A (es) Factor viii modificado.
ZA200007669B (en) Insert.
ZA200210206B (en) Expression system.
ZA200107824B (en) Apparatus.
EG23262A (en) Delta -pyrrolines.
ZA200103011B (en) Dispersions.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03005735A (es) Muelle hidraulico.
ZA200205389B (en) Booklet.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03001991A (es) Novedosas arilalcano-sulfonamidas.
MXPA03005714A (es) Sulfamidotienopirimidinas.
MXPA03002411A (es) 4-amino-quinazolinas.
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
MXPA03005494A (es) Benzoilpiridazinas.
ZA200206150B (en) Aminomethyl-phenyl-cyclohexanone derivatives.
MXPA03002521A (es) Triazol-epotilona.
GB0002612D0 (en) C.m.e
GB0007510D0 (en) D.o.t.t.s
GB0024269D0 (en) D.p.s.

Legal Events

Date Code Title Description
FG Grant or registration